Search Results - "van Baar, Annieke C."

Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study by van Baar, Annieke C G, Holleman, Frits, Crenier, Laurent, Haidry, Rehan, Magee, Cormac, Hopkins, David, Rodriguez Grunert, Leonardo, Galvao Neto, Manoel, Vignolo, Paulina, Hayee, Bu'Hussain, Mertens, Ann, Bisschops, Raf, Tijssen, Jan, Nieuwdorp, Max, Guidone, Caterina, Costamagna, Guido, Devière, Jacques, Bergman, Jacques J G H M

“…The duodenum has become a metabolic treatment target through bariatric surgery learnings and the specific observation that bypassing, excluding or altering…”
Get more information

Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and Obesity by Busch, Celine B E, Bergman, Jacques J G H M, Nieuwdorp, Max, van Baar, Annieke C G

“…The metabolic syndrome (MetSyn) is currently one of the biggest global health challenges because of its impact on public health. MetSyn includes the cluster of…”
Get full text

Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling? by van Baar, Annieke C G, Meiring, Suzanne, Holleman, Frits, Hopkins, David, Mingrone, Geltrude, Devière, Jacques, Nieuwdorp, Max, Bergman, Jacques J G H M

Get more information

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial by Mingrone, Geltrude, van Baar, Annieke Cg, Devière, Jacques, Hopkins, David, Moura, Eduardo, Cercato, Cintia, Rajagopalan, Harith, Lopez-Talavera, Juan Carlos, White, Kelly, Bhambhani, Vijeta, Costamagna, Guido, Haidry, Rehan, Grecco, Eduardo, Galvao Neto, Manoel, Aithal, Guruprasad, Repici, Alessandro, Hayee, Bu'Hussain, Haji, Amyn, Morris, A John, Bisschops, Raf, Chouhan, Manil D, Sakai, Naomi S, Bhatt, Deepak L, Sanyal, Arun J, Bergman, J J G H M

“…Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority randomised controlled trial,…”
Get more information

A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study by Meiring, Suzanne, van Baar, Annieke C G, Sørensen, Nikolaj, Holleman, Frits, Soeters, Maarten R, Nieuwdorp, Max, Bergman, Jacques J G H M

“…The gut microbiota influences and interacts with the host metabolism through effects on nutrient metabolism and digestion. Duodenal Mucosal Resurfacing (DMR)…”
Get full text

Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting by Haidry, Rehan J., van Baar, Annieke C., Galvao Neto, Manoel P., Rajagopalan, Harith, Caplan, Jay, Levin, Philip S., Bergman, Jacques J., Rodriguez, Leonardo, Deviere, Jacques, Thompson, Christopher C.

“…We aimed to develop duodenal mucosal resurfacing (DMR), a minimally invasive upper endoscopic hydrothermal ablation procedure, to treat insulin-resistant…”
Get full text

Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study by van Baar, Annieke C.G., Meiring, Suzanne, Smeele, Paul, Vriend, Tessa, Holleman, Frits, Barlag, Marjon, Mostafavi, Nahid, Tijssen, Jan G.P., Soeters, Maarten R., Nieuwdorp, Max, Bergman, Jacques J.G. H.M.

“…Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves glycemic control…”
Get full text

Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study by Busch, Celine B.E., Meiring, Suzanne, van Baar, Annieke C.G., Gastaldelli, Amalia, DeFronzo, Ralph, Mingrone, Geltrude, Hagen, Moira, White, Kelly, Rajagopalan, Harith, Nieuwdorp, Max, Bergman, Jacques J.G.H.M.

“…The duodenum has been shown to play a key role in glucose homeostasis. Duodenal mucosal resurfacing (DMR) is an endoscopic procedure for patients with type 2…”
Get full text

The Duodenum harbors a Broad Untapped Therapeutic Potential by van Baar, Annieke C.G., Nieuwdorp, Max, Holleman, Frits, Soeters, Maarten R., Groen, Albert K., Bergman, Jacques J.G.H.M.

Get full text

Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes by Meiring, Suzanne, Meessen, Emma C E, van Baar, Annieke C G, Holleman, Frits, Nieuwdorp, Max, Olde Damink, Steven W, Schaap, Frank G, Vaz, Fred M, Groen, Albert K, Soeters, Maarten R, Bergman, Jacques J G H M

“…Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes…”
Get more information

Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study) by van Baar, Annieke C.G., Devière, Jacques, Hopkins, David, Crenier, Laurent, Holleman, Frits, Galvão Neto, Manoel P., Becerra, Pablo, Vignolo, Paulina, Rodriguez Grunert, Leonardo, Mingrone, Geltrude, Costamagna, Guido, Nieuwdorp, Max, Guidone, Caterina, Haidry, Rehan J., Hayee, Bu, Magee, Cormac, Carlos Lopez-Talavera, Juan, White, Kelly, Bhambhani, Vijeta, Cozzi, Emily, Rajagopalan, Harith, J.G.H.M. Bergman, Jacques

“…•We demonstrate long-term safety and tolerability of DMR in patients with T2D.•HbA1c was significantly reduced at 24 months post-DMR.•Over 50% of patients…”
Get full text

Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites by van Baar, Annieke C G, Prodan, Andrei, Wahlgren, Camilla D, Poulsen, Steen S, Knop, Filip K, Groen, Albert K, Bergman, Jacques J, Nieuwdorp, Max, Levin, Evgeni

“…Background Enteroendocrine cells are essential for the regulation of glucose metabolism, but it is unknown whether they are associated with clinical features…”
Get full text

1156-P: Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1 RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes by SMEELE, PAUL, VAN BAAR, ANNIEKE C., VRIEND, TESSA M., HOLLEMAN, FRITS, SOETERS, MAARTEN, NIEUWDORP, MAX, TIJSSEN, JAN, BERGMAN, JACQUES J.

“…Background: Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves…”
Get full text

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results by van Baar, Annieke C.G., Beuers, Ulrich, Wong, Kari, Haidry, Rehan, Costamagna, Guido, Hafedi, Alia, Deviere, Jacques, Ghosh, Soumitra S., Lopez-Talavera, Juan Carlos, Rodriguez, Leonardo, Galvao Neto, Manoel P., Sanyal, Arun, Bergman, Jacques J.G.H.M.

“…Insulin resistance is a core pathophysiological defect underscoring type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Both…”
Get full text

Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus by van Baar, Annieke C.G., Haidry, Rehan, Rodriguez Grunert, Leonardo, Galvao, Manoel P. Neto, Bisschops, Raf, Hayee, Bu Hussain, Costamagna, Guido, Deviere, Jacques, Bergman, Jacques J.G.H.M.

“…Abstract Background and study aims  Duodenal mucosal resurfacing (DMR) is an endoscopic procedure which improves insulin resistant metabolic disease, including…”
Get full text

IMPROVEMENTS IN INSULIN SENSITIVITY SEEN IN PATIENTS WITH TYPE 2 DIABETES AFTER REVITA® DMR IS ASSOCIATED WITH A DECREASE IN GLUCAGON, GLUCOSE, AND GIP AFTER A MIXED MEAL TOLERANCE TEST by Busch, Celine, Meiring, Suzanne, Van Baar, Annieke C., White, Kelly, Lopez-Talavera, Juan Carlos, Hagen, Moira, Nieuwdorp, Max, Bergman, Jacques

Get full text

Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study by Busch, Celine B.E., Meiring, Suzanne, van Baar, Annieke C.G., Holleman, Frits, Nieuwdorp, Max, Bergman, Jacques J.G.H.M.

“…Studies have shown that hydrothermal duodenal mucosal ablation results in improved glycemic control. Recellularization via electroporation therapy (ReCET) is a…”
Get full text

Response by van Baar, Annieke C G, Bergman, Jacques J G H M

Get full text

Response by van Baar, Annieke C G, Bergman, Jacques J G H M

Get full text

Re-Cellularization via Electroporation Therapy of the duodenum combined with GPL-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes; 12 months results of a first-in-human study by Busch, Celine B E, Meiring, Suzanne, van Baar, Annieke C G, Holleman, Frits, Nieuwdorp, Max, Bergman, Jacques J G H M

“…Studies have shown that hydrothermal duodenal mucosal ablation results in improved glycemic control. Re-Cellularization via Electroporation Therapy (ReCET) is…”
Get full text